Compare Cassava Sciences Inc (FLNA) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Texas Instruments Incorporated — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while Texas Instruments Incorporated trades at $289.26 (market cap $274.11B). The key difference: Texas Instruments Incorporated is far larger — about 5158.3× Cassava Sciences Inc's market cap, and Texas Instruments Incorporated pays a 1.89% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | TXN | |
|---|---|---|
Market Cap | $53.14M | $274.11B |
Sector | Health | Technology |
52-Week High | $4.64 | $332.35 |
52-Week Low | $1.09 | $153.33 |
Enterprise Value | -$33.43M | $283.06B |
Dividend Yield | — | 1.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Texas Instruments (TXN) trades at $305.55, up 2.34% with a bullish technical signal. Recent Q1 2026 earnings beat expectations, with revenue growth to $17.68 billion in 2025. The company maintains strong profitability with 29.11% net margin and announced a CFO transition with Julie Knecht succeeding Rafael Lizardi in August 2026. Analysts show a buy consensus with a $317.20 price target, though valuation ratios like P/E of 52.23 appear elevated.
Outlook remains positive driven by AI data center demand and 300mm capacity expansion, but risks include high debt-to-asset ratio of 40.61% and competitive pressures. The stock presents growth potential with disciplined risk management advised given premium valuation and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
